Risankizumab Induces Early Clinical Remission and Response in Patients With Moderate-To-Severe Crohn's Disease: Results From the Phase 3 ADVANCE and MOTIVATE Studies

被引：0

作者：

Schreiber, Stefan ^{[1
]}

Ferrante, Marc ^{[2
]}

Panaccione, Remo ^{[3
]}

Colombel, Jean-Frederic ^{[4
]}

Hisamatsu, Tadakazu ^{[5
]}

Lim, Allen ^{[6
]}

Lindsay, James ^{[7
]}

Rubin, David T.

Sandborn, William ^{[8
]}

Neimark, Ezequiel ^{[9
]}

Song, Alexandra ^{[9
]}

Liao, Xiaomei ^{[9
]}

Feng, Tian ^{[9
]}

Berg, Sofie ^{[9
]}

Wallace, Kori ^{[9
]}

D'Haens, Geert ^{[10
]}

机构：

[1] Univ Kiel, Univ Hosp Schleswig Holstein, Kiel, Schleswig Holst, Germany

[2] Univ Hosp Leuven, Leuven, Luxembourg, Belgium

[3] Univ Calgary, Cumming Sch Med, Inflammatory Bowel Dis Clin, Gastrointestinal Res, Calgary, AB, Canada

[4] Icahn Sch Med Mt Sinai, New York, NY 10029 USA

[5] Kyorin Univ, Sch Med, Tokyo, Japan

[6] John Flynn Private Hosp, Tugun, Qld, Australia

[7] Queen Mary Univ London, London, England

[8] Univ Calif San Diego, La Jolla, CA 92093 USA

[9] AbbVie Inc, N Chicago, IL USA

[10] Amsterdam Univ Med Ctr, Amsterdam, Noord Holland, Netherlands

来源：

AMERICAN JOURNAL OF GASTROENTEROLOGY | 2021年 / 116卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

S695

引用

页码：S314 / S315

页数：2

共 50 条

[1] Risankizumab induces early clinical remission and response in patients with Moderate-to-Severe Crohn's Disease: Results from the phase 3 ADVANCE and MOTIVATE studies
Schreiber, S. W.
Ferrante, M.
Panaccione, R.
Colombel, J. F.
Hisamatsu, T.
Lim, A.
Lindsay, J. O.
Rubin, D. T.
Sandborn, W. J.
Neimark, E.
Song, A. P.
Liao, X.
Feng, T.
Berg, S.
Wallace, K.
D'Haens, G. R.
[J]. JOURNAL OF CROHNS & COLITIS, 2021, 15 : S026 - S027
[2] Risankizumab Therapy Induces Improvements in Endoscopic Endpoints in Patients With Moderate-To-Severe Crohn's Disease: Results From the Phase 3 ADVANCE and MOTIVATE Studies
Bossuyt, Peter
Ferrante, Marc
Baert, Filip
Danese, Silvio
Feagan, Brian
Loftus, Edward V.
Panes, Julian
Peyrin-Biroulet, Laurent
Ran, Zhihua
Armuzzi, Alessandro
D'Haens, Geert
Song, Alexandra
Neimark, Ezequiel
Liao, Xiaomei
Zhou, Qian
Berg, Sofie
Wallace, Kori
Panaccione, Remo
[J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2021, 116 : S357 - S358
[3] Risankizumab therapy induces improvements in endoscopic endpoints in patients with Moderate-to-Severe Crohn's Disease: Results from the phase 3 ADVANCE and MOTIVATE studies
Bossuyt, P.
Ferrante, M.
Baert, F.
Danese, S.
Feagan, B. G.
Loftus, E. V., Jr.
Panes, J.
Peyrin-Biroulet, L.
Ran, Z.
Armuzzi, A.
D'Haens, G. R.
Song, A.
Neimark, E.
Liao, X.
Zhou, Q.
Berg, S.
Wallace, K.
Panaccione, R.
[J]. JOURNAL OF CROHNS & COLITIS, 2021, 15 : S033 - S034
[4] Risankizumab Induction Therapy in Patients With Moderate-to-Severe Crohn's Disease with Intolerance or Inadequate Response to Conventional and/or Biologic Therapy: Results from the Phase 3 ADVANCE Study
D'Haens, Geert R.
Colombel, Jean Frederic
Bossuyt, Peter
Danese, Silvio
Lim, Allen
Lindsay, James
Hisamatsu, Tadakazu
Ran, Zhihua
Rubin, David T.
Neimark, Ezequiel
Huang, Bidan
Liao, Xiaomei
Berg, Sofie
Duan, W. Rachel
Wallace, Kori
Sandborn, William J.
[J]. GASTROENTEROLOGY, 2021, 161 (02) : E28 - E28
[5] Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials
D'Haens, Geert
Panaccione, Remo
Baert, Filip
Bossuyt, Peter
Colombel, Jean-Frederic
Danese, Silvio
Dubinsky, Marla
Feagan, Brian G.
Hisamatsu, Tadakazu
Lim, Allen
Lindsay, James O.
Loftus, Edward V., Jr.
Panes, Julian
Peyrin-Biroulet, Laurent
Ran, Zhihua
Rubin, David T.
Sandborn, William J.
Schreiber, Stefan
Neimark, Ezequiel
Song, Alexandra
Kligys, Kristina
Pang, Yinuo
Pivorunas, Valerie
Berg, Sofie
Duan, W. Rachel
Huang, Bidan
Kalabic, Jasmina
Liao, Xiaomei
Robinson, Anne
Wallace, Kori
Ferrante, Marc
[J]. LANCET, 2022, 399 (10340): : 2015 - 2030
[6] Normalisation of biomarkers and improvement in clinical outcomes in patients with Crohn's Disease treated with risankizumab in the phase 3 ADVANCE, MOTIVATE, and FORTIFY studies
Atreya, R.
Feagan, B.
Shchukina, O.
Jairath, V.
Rieder, F.
Hisamatsu, T.
Siegmund, B.
Rizzo, J.
Kligys, K.
Neimark, E.
Song, A.
Zambrano, J.
Mallick, M.
Cheng, E.
Armuzzi, A.
[J]. JOURNAL OF CROHNS & COLITIS, 2022, 16 : I126 - I127
[7] NORMALISATION OF BIOMARKERS AND IMPROVEMENT IN CLINICAL OUTCOMES IN PATIENTS WITH CROHN'S DISEASE TREATED WITH RISANKIZUMAB IN THE PHASE 3 ADVANCE, MOTIVATE, AND FORTIFY STUDIES
Atreya, Raja
Feagan, Brian G.
Shchukina, Oksana
Jairath, Vipul
Rieder, Florian
Hisamatsu, Tadakazu
Siegmund, Britta
Rizzo, Joanne
Kligys, Kristina
Neimark, Ezequiel
Song, Alexandra P.
Zambrano, Javier A.
Mallick, Madhuja
Cheng, Erica
Armuzzi, Alessandro
[J]. GASTROENTEROLOGY, 2022, 162 (07) : S978 - S979
[8] Effect of risankizumab on health-related quality of life in patients with Crohn's disease: results from phase 3 MOTIVATE, ADVANCE and FORTIFY clinical trials
Peyrin-Biroulet, Laurent
Ghosh, Subrata
Lee, Scott D.
Lee, Wan-Ju
Griffith, Jenny
Wallace, Kori
Berg, Sofie
Liao, Xiaomei
Panes, Julian
Loftus, Edward V., Jr.
Louis, Edouard
[J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2023, 57 (05) : 496 - 508
[9] Risankizumab Versus Ustekinumab for the Achievement of Endoscopic Outcomes in Patients With Moderate-to-Severe Crohn's Disease: Results From the Phase 3b SEQUENCE Trial
Peyrin-Biroulet, L.
Bossuyt, P.
Regueiro, M.
Schreiber, S.
Gecse, K.
Irving, P.
D'Haens, G.
Cao, Q.
Neimark, E.
Huang, X.
Anschutz, T.
Kligys, K.
O'Brien, D.
Panaccione, R.
[J]. JOURNAL OF CROHNS & COLITIS, 2024, 18 : I90 - I91
[10] Shorter disease duration is associated with better outcomes in patients with moderately to severely active Crohn's Disease treated with risankizumab: Results from the phase 3 ADVANCE, MOTIVATE, and FORTIFY studies
Peyrin-Biroulet, L.
Colombel, J. F.
Louis, E.
Ferrante, M.
Motoya, S.
Panaccione, R.
Torres, J.
Ungaro, R. C.
Kligys, K.
Kalabic, J.
Zambrano, J.
Zhang, Y.
D'Haens, G. R.
[J]. JOURNAL OF CROHNS & COLITIS, 2022, 16 : I046 - I048

← 1 2 3 4 5 →